论文部分内容阅读
目的探讨头孢哌酮钠单用与联合舒巴坦治疗医院获得性肺炎(HAP)的疗效及药物经济学的差异。方法选取HAP患者154例,头孢哌酮钠治疗的78例患者为观察组,头孢哌酮钠联合舒巴坦治疗的76例患者为对照组,比较2组临床疗效和成本效果。结果观察组痊愈率、治疗有效率和不良反应发生率为84.62%、84.27%和5.13%,与对照组(92.12%、89.06%和6.58%)比较差异无统计学意义(P>0.05),2组患者的细菌清除率比较其差异无统计学意义(P>0.05);2组患者住院费用分别为(4534.85±862.31)元,(6737.13±1036.47)元,差异有统计学意义,且观察组成本效果比(53.99)明显低于对照组(73.23),差异有统计学意义(P<0.05)。结论头孢哌酮钠单用与联合舒巴坦治疗医院获得性肺炎的临床疗效相近,单用头孢哌酮钠成本效果更佳。
Objective To investigate the efficacy and pharmacological economics of cefoperazone sodium combined with sulbactam in the treatment of hospital acquired pneumonia (HAP). Methods A total of 154 patients with HAP, 78 patients treated with cefoperazone sodium were selected as the observation group and 76 patients treated with cefoperazone sodium and sulbactam as the control group. The clinical efficacy and cost-effectiveness were compared between the two groups. Results The cure rate, treatment effective rate and adverse reaction rate in the observation group were 84.62%, 84.27% and 5.13%, respectively, which were not significantly different from those in the control group (92.12%, 89.06% and 6.58%) (P> 0.05) (P> 0.05). The hospitalization costs of the two groups were (4534.85 ± 862.31) yuan and (6737.13 ± 1036.47) yuan respectively, the difference was statistically significant, and the cost of the observation group The effect ratio (53.99) was significantly lower than the control group (73.23), the difference was statistically significant (P <0.05). Conclusion Cefoperazone sodium combined with sulbactam alone in the treatment of hospital-acquired pneumonia clinical efficacy similar single Cefoperazone sodium cost better.